RecruitingEarly Phase 1NCT05087745

A Clinical Study on TIL for the Treatment of Advanced Solid Tumors

A Clinical Study on Tumor Infiltrating Lymphocytes for the Treatment of Advanced Solid Tumors

Sponsor

Shanghai Juncell Therapeutics

Enrollment

50 participants

Start Date

Dec 10, 2021

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumor Treatment Side Effects Effects of Immunotherapy Tumor Infiltrating Lymphocytes

Summary

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Tumor Infiltrating Lymphocytes for people with advanced solid tumor, effects of immunotherapy, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALTumor Infiltrating Lymphocytes

Adoptive transfer of 1x10\^9-5x10\^10 autologous TILs to patients i.v. in 30-120 minutes.

Locations(1)

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine

Hangzhou, Zhejiang, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05087745

Related Trials

Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

NCT0485565622 locations

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

NCT052597091 location